Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TeclisAMY trial: what clinicians have said so far
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
- NCT06649695 ↗
- Active, not recruiting
- European Myeloma Network B.V.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on TeclisAMY yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TeclisAMY so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- AL Amyloidosis
- Interventions
- Teclistamab
- Arms
- Teclistamab · Experimental
- Enrollment
- 30
- Primary outcomes
- Hematologic Complete Response (CR) rate
- Sponsor
- European Myeloma Network B.V. with Janssen Research & Development, LLC
- Start
- Jul 2, 2025
- Primary completion
- Sep 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06649695 · updated Jul 20, 2026